Mode
Home
Research
Clinical Trials Drug Pipeline Weekly Digests
Reference
Conditions Medications
Community
Questions
Text Size
Log in / Sign up
Home › Medications › Telaprevir

Telaprevir

0 published articles · Updated continuously

Clinical Trial Landscape

Clinical Trials of Telaprevir

22 trials tracked of Telaprevir: 10 in phase 3 or 4 and 1 with published results. The most-cited published study has 151 citations.

22Trials tracked
10Phase 3 & 4
0Recruiting
1With published results
Phase distribution
Phase 3 10 Phase 2 10 Phase 1 1 Other / NA 1
  1. Phase 3 Phase 3 Efficacy and Safety Study of Peginterferon Lambda-1a and Ribavirin With Telaprevir Completed · 151 cited
  2. Phase 3 Open-Label, Bridging Study of Telaprevir in Treatment-Naïve and Treatment-Experienced Russian Patients With Genotype 1 Chronic Hepatitis C Completed
  3. Phase 3 VX-950-TiDP24-C219: A Roll Over Trial for Patients in the Control Group of the C216 Study Who Received Telaprevir Placebo Completed
  4. Phase 3 VX-950-C211 - A Dosing Regimen Study (Twice Daily Versus Every 8 Hours) of Telaprevir in Treatment-naïve Participants With Genotype 1 Chronic Hepatitis C Virus Infection Completed
  5. Phase 3 A Phase 3 Study of Telaprevir in Combination With Pegasys® and Copegus® in Treatment-Naive Subjects With Genotype 1 Hepatitis C Virus (HCV) Completed
  6. Phase 3 A Study to Evaluate the Efficacy and Safety of Three Experimental Drugs Compared With Telaprevir (a Licensed Product) in People With Hepatitis C Virus Infection Who Have Not Had Treatment Before Completed
Show 16 more trials
  1. Phase 3 Study Comparing Daclatasvir (BMS-790052) With Telaprevir Combined With Peginterferon Alfa-2a and Ribavirin in Patients With Chronic Hepatitis C Virus Infection Completed
  2. Phase 3 A Study Evaluating 24-Week and 48-Week Telaprevir-Based Regimen in Treatment Naïve Subjects With Genotype 1 Chronic Hepatitis C Who Achieve an Extended Rapid Viral Response Completed
  3. Phase 3 A Study to Evaluate the Efficacy and Safety of Three Experimental Drugs Compared With Telaprevir (a Licensed Product) for Treatment of Chronic Hepatitis C Infection in Treatment-experienced Adults Completed
  4. Phase 3 A Safety and Effectiveness Study of Telaprevir in Chronic, Genotype 1, Hepatitis C Patients That Failed Previous Standard Treatment Completed
  5. Phase 2 Chronic Hepatitis C Virus Related Thrombocytopenia to Evaluate the Effects of E5501 Completed
  6. Phase 2 An Exploratory Study of Telaprevir in Treatment-Naive Participants With Chronic Genotype 4 Hepatitis C Virus Infection Completed
  7. Phase 2 Dose Ranging of GSK2336805 in Combination Therapy Completed
  8. Phase 2 An Open-Label Study of Telaprevir Administered Every 12 or 8 Hours in Combination With One of Two Pegylated Interferons and Ribavirin in Treatment-Naive Genotype 1 Chronic Hepatitis C Participants Completed
  9. Phase 2 Phase 2 Study of VX-950, Pegasys® With and Without Copegus® in Hepatitis C Completed
  10. Phase 2 Intrahepatic HCV RNA and Telaprevir Kinetics in Hepatitis C Virus (HCV) Completed
  11. Phase 2 A Study of Telaprevir (VX-950), Pegasys and Copegus in Hepatitis C (PROVE3) Completed
  12. Phase 2 Phase 2 Study of VX-950, Pegasys®, and Copegus® in Hepatitis C Completed
  13. Phase 2 A Rollover Study for Subjects Participating in the Control Arm of Study VX06-950-106, VX05-950-104 and VX05-950-104EU Whose Plasma Hepatitis C Virus (HCV) Ribonucleic Acid (RNA) Levels Did Not Respond to Therapy Completed
  14. Phase 2 A Phase 2a Study to Evaluate Viral Kinetics and Safety of Telaprevir in Participants With Genotype 2 or 3 Hepatitis C Infection Completed
  15. Phase 1 Viral Kinetics in HCV Clearance in Subjects With Hemophilia Completed
  16. N/A An Observational Study on Dual And Triple Therapies Based on Peginterferon Alfa (e.g. Pegasys) in Patients With Chronic Hepatitis C Completed

Showing the 22 most-cited and recently-updated of 22 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
No published articles yet for this medication. Check back soon.